Expression of PD-1 in peripheral blood of the patients with HIV/AIDS and its clinical significance
CHEN Chen1, ZHAO Chang-cheng2, WANG Yong1, XV Qian-ming1, LIU Ya1
1. College of Animal Science and Technology, Anhui Agricultural University, Hefei 230022, China; 2. Department of Infectious Disease Hospital of Anhui Provincial Hospital, Hefei 230022, China
Abstract：In order to investigate the effect of HIV infection and antiviral therapy on expression of programmed death-1 (PD-1), 61 cases of HIV / AIDS patients were divided into treatment group and untreated group, 35 healthy people were taken as negative controls, expression of PD-1 mRNA were detected utilizing semi-quantitative reverse transcription and polymerase chain reaction. The levels of sPD-1 in serum were determined by enzyme linked immunosorbent assay (ELISA). The differences of serum sPD-1 in HIV / AIDS patients with different CD4+ T lymphocyte levels were also compared. The results showed that the relative expression level of PD-1 mRNA in untreated group, treatment group and healthy group were 0.337 8±0.064, 0.578 2±0.073 and 0.771 5±0.124, respectively. There was significant difference between healthy group and untreated group (P<0.001). And also significant difference were found between healthy group and treated group,treated group and untreated group, respectively (P=0.031, P=0.043). The serum sPD-1 levels in untreated group, treatment group and healthy group were 42.22±2.21 ng/mL, 38.24±2.79 ng/mL and 29.88±1.41 ng/mL, respectively. There were significant difference between the healthy group and the untreated group, the healthy group and the treated group, and between the untreated group and the treated group (P=0.008, P=0.040, P=0.020). Moreover, the serum sPD-1 levels of CD4+T lymphocytes <350 cells/mm3 in untreated group and treatment group were significantly higher than those in CD4+T lymphocyte count >350 cells / mm3 (P=0.035, P=0.047) .In conclusion, antiviral therapy down-regulates high level sPD-1 expression to a certain extent to recovery of PD-1 / PD-L1 pathway and promote the immune reconstitution. Monitoring the expression of PD-1 mRNA and sPD-1 is of value in auxiliary diagnosis and inferred prognosis of HIV.
陈琛, 赵长城, 王勇, 徐前明, 刘亚. HIV/AIDS患者外周血程序性死亡受体-1的表达及临床意义[J]. 中国人兽共患病学报, 2019, 35(4): 320-323.
CHEN Chen, ZHAO Chang-cheng, WANG Yong, XV Qian-ming, LIU Ya. Expression of PD-1 in peripheral blood of the patients with HIV/AIDS and its clinical significance. Chinese Journal of Zoonoses, 2019, 35(4): 320-323.
[1] 张福杰, 王健, 王福生, 等. 国家免费艾滋病抗病毒药物治疗手册[M]. 北京:人民卫生出版社, 2012: 6-7. [2] Carter L, Fouser LA, Jussif J, et al.PD-1:PD-L1 inhibitory pathway affects both CD4(+)and CD8(+)T cells and is overcome by IL-2[J]. Eur J Immunol, 2002, 32:634-643. [3] 谢荣华, 欧阳珊珊. HIV/AIDS 患者程序死亡分子1的表达与合并机会性感染的关系[J]. 广东医学, 2013, 34(4): 538-541. DOI: 10.13820/j.cnki.gdyx.2013.04.016 [4] Fromentin R, Bakeman W, Lawani MB, et al.CD4+T Cells Expressing PD-1,TIGIT and LAG-3 Contribute to HIV persistence during ART[J]. PLoS Pathog, 2016,12(7):e1005761. DOI: 10.1371/journal.ppat.1005761 [5] Edward S, Dudek TE, Allen TM, et al.PD-1 blockade in chronically HIV-1 infected humanized mice suppresses viral loads[J]. PLoS One, 2013, 10:e77780. DOI:10.1371/journal.pone.0077780 [6] 王硕, 曲秀娟, 刘云鹏. 可溶性PD-1、PD-L1分子在肿瘤免疫中研究进展[J]. 临床军医杂志, 2015, 12(43): 1308-1311. DOI: 10.16680/j.1671-3826.2015.12.32 [7] He YF, Zhang GM, Wang XH, et al.Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine[J]. J Immunol, 2004, 173(8):4919-492. DOI:10.4049/jimmunol.173.8.4919 [8] Geng H, Zhang GM, Xiao H, et al.HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma[J]. Int J Cancer, 2006, 118(11):2657-2664. DOI:10.1002/ijc.21795 [9] Onlamoon N, Rogers K, Mayne AE, et al.Soluble PD-1 rescues the proliferativeresponse of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection[J]. Immunology, 2008, 124(2):277-293. DOI:10.1111/j.1365-2567.2007.02766.x [10] Wu H, Miao M, Zhang G, et al.Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia[J]. Immunol Invest, 2009,38(5):408-421. DOI: 10.1080/08820130902912332 [11] Nielsen C, Ohm-Laursen L, Barington T, et al.Alternative splice variants of the human PD-1 gene[J]. Cell Immunol, 2005,235(2):109-116. DOI: 10.1016/j.cellimm.2005.07.007 [12] Wan B, Nie H, Liu A, et al.Aberrant regulation of synovial T cell activation by soluble costimulatory moleculaes in rheumatoid arthritis[J]. J Immunol, 2006, 177(12):8844-8850. [13] Wang D, Zhou D, Du Q, et al.Aberrant production of soluble indecible T-cell co-stimulator(sICOS) and soluble programmed cell death protein 1(sPD-1) in patients with chronic hepatitis C[J]. Mol Med Rep, 2013, 7(4):1197-1202. DOI:10.3892/mmr.2013.1326 [14] Her M, Kim D, Oh M, et al.Increased expression of soluble inducible costimulator ligand(ICOSL) in patients with systemic lupuerythematosus[J]. Lupus, 2009, 18(6):501-507. DOI: 10.1177/0961203308099176
2019, Vol. 35 
